U.S. The coronavirus vaccine is overexcessful, which has affected the performance of vaccine companies.
htmlOn October 7, American vaccine company Novavax issued an announcement stating that will pay 185 million US dollars in compensation to Diosynth Biotechnology, a subsidiary of Fujifilm , canceling the order for the new crown vaccine.
Novavax is the fourth approved COVID-19 vaccine in the United States after Pfizer , Moderna, and Johnson & Johnson . It uses recombinant protein technology and is vaccinated in two doses throughout the process. On July 14 this year, the US FDA approved the launch of the vaccine, At that time, the US government announced the purchase of 3.2 million doses of this vaccine .
Novavax said at the time that they hope to attract people who do not trust Pfizer and Moderna mRNA vaccines . After all, at that time, about 22% of the people in the United States had never received the COVID-19 vaccine.
However, according to the latest disclosed data, the Novavax vaccine has not been recognized by the market after it was approved. According to data disclosed by the U.S. Centers for Disease Control and Prevention, in more than two months to early October, about 841,000 doses of the new crown vaccine of Novavax were actually delivered, but only 32,992 doses of were vaccinated, far lower than expected.
Novavax company took great pains to make the vaccine available to market quickly. They first found Emergent, a CDMO company in the United States. However, because the vaccine development speed was slow, the set production line was pried away by Johnson & Johnson at a high price, so they had to turn to seek the CDMO subsidiary of Fujifilm . This CDMO subsidiary of
Fujifilm is also very well-known. The company, called Diosynth, was founded in 2011 and is headquartered in North Carolina, USA. In 2021, the CDMO company achieved revenue of $124 million . In recent years, as biopharmaceuticals receive more and more OEM orders, Fujifilm has decided to build branches in the UK and Denmark to expand CDMO production capacity.
originally planned to hand over to Fujifilm once and for all, but unexpectedly, there was almost no market for its own vaccine. Novavax had to admit defeat after less than three months of the vaccine being released.
In the announcement, Novavax said that it will pay US$185 million in settlement to the subsidiary of Fujifilm to terminate the CDMO cooperative production activities. The money will be paid in four quarters starting on March 31, 2023, with a quarterly payment of US$34.3 million.
Fujifilm was also depressed. The company said that it will work harder in business to find manufacturing business and offset the losses caused by capacity vacancy.
At present, The United States has received more than 230 million doses of Moderna vaccine, as well as 370 million doses of mRNA vaccine , jointly produced by Pfizer and BioNTech.
committed | Jiating
edited | Jiang Yun
operation | 23
illustration | Visual China
#New crown vaccine##US new crown epidemic#
